Idiopathic Pulmonary Fibrosis

Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.

In the last 3 months of life, health care costs were significantly lower for patients receiving multidisciplinary collaborative care than for patients receiving specialized care or nonspecialized care. The differences in costs were primarily driven by differences in hospitalizations and emergency department visits.

The study sought to determine whether patient-reported outcomes are linked with death beyond clinical risk factors in patients with idiopathic pulmonary fibrosis (IPF).

Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, according to study findings.

Researchers highlight new therapeutic attempts and potential future approaches to treating idiopathic pulmonary fibrosis, a chronic, fibrosing idiopathic interstitial lung disease.

In a study to be presented at the American Thoracic Society (ATS) Annual Meeting, held in Dallas, Texas on May 17-22, 2019, researchers investigated visit-to-visit variability in the forced vital capacity (FVC) of patients with idiopathic pulmonary fibrosis (IPF).

During the American Thoracic Society’s Annual Meeting in Dallas, Texas, taking place May 17-22, 2019, researchers will present findings from a study investigating pirfenidone (Esbriet) in the treatment of idiopathic pulmonary fibrosis (IPF) in a real-world setting.